Nicolas Mottet
A5053854071- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Hormonal and reproductive studies
- Testicular diseases and treatments
- Genital Health and Disease
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Sexual Differentiation and Disorders
- Urinary and Genital Oncology Studies
- Health Systems, Economic Evaluations, Quality of Life
- Urinary Bladder and Prostate Research
- Colorectal Cancer Screening and Detection
- Genomics, phytochemicals, and oxidative stress
- Clinical practice guidelines implementation
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- MRI in cancer diagnosis
- Estrogen and related hormone effects
- COVID-19 and healthcare impacts
Clinique Mutualiste Chirurgicale
2006-2024
Centre Hospitalier Universitaire de Saint-Étienne
2015-2024
Total (France)
2017-2024
Institute Cancer De La Loire Lucien Neuwirth
2017-2024
Université Jean Monnet
2014-2023
Hôpital Nord
2014-2023
European Association of Urology
2020-2023
University of Turin
2023
Institute of Oncology Research
2022
Tampere University
2022
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
Abstract Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker evaluating response to therapy, but lacks established criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, Amsterdam, The Netherlands, formulate criteria PSMA PET/CT-based patients treated metastatic optimal timing use it. Methods Panelists received thematic topics...